We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
-$396M
Cap. Flow %
-22.17%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Healthcare 10.45%
2 Energy 0.15%
3 Communication Services 0%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RMTI icon
51
PUT
Rockwell Medical
RMTI
$27.6M
$7.16M 0.4%
51
+33
+183% +$42.9K
CLVS
52
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
$6.93M 0.39%
+1,000
New +$73.4K
IONS icon
53
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$6.84M 0.38%
1,584
+1,454
+1,118% +$70.5K
XBI icon
54
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$6.23M 0.35%
+131,235
New +$6.72M
CDMO
55
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$6.02M 0.34%
+34,058
New +$448K
RPRX
56
PUT
DELISTED
Repros Therapeutics Inc.
RPRX
$5.98M 0.34%
3,371
+436
+15% +$8.44K
ARIA
57
CALL
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$5.82M 0.33%
7,220
+2,340
+48% +$18.2K
IOC
58
PUT
DELISTED
Interoil Corporation
IOC
$5.8M 0.33%
+895
New +$49.4K
INCY icon
59
CALL
Incyte
INCY
$26B
$5.6M 0.31%
1,046
+615
+143% +$38.2K
QURE icon
60
uniQure
QURE
$2.52B
$5.5M 0.31%
+354,000
New +$5.65M
PBYI icon
61
CALL
Puma Biotechnology
PBYI
$406M
$5.33M 0.3%
512
+320
+167% +$37.6K
AMGN icon
62
Amgen
AMGN
$212B
$5.22M 0.29%
+42,311
New +$5.13M
REGN icon
63
Regeneron Pharmaceuticals
REGN
$72.9B
$5.16M 0.29%
+17,191
New +$5.3M
ACHN
64
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$4.83M 0.27%
14,693
-7,886
-35% -$27.6K
ARIA
65
PUT
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$4.82M 0.27%
5,981
+3,672
+159% +$28.6K
UTHR icon
66
CALL
United Therapeutics
UTHR
$26.1B
$4.8M 0.27%
+510
New +$52.2K
LUMO
67
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$4.76M 0.27%
186
-356
-66% -$109K
CEMP
68
DELISTED
Cempra, Inc.
CEMP
$4.69M 0.26%
405,946
+168,946
+71% +$2.1M
TMO icon
69
Thermo Fisher Scientific
TMO
$214B
$4.64M 0.26%
+38,630
New +$4.59M
CBST
70
PUT
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$4.41M 0.25%
603
-2,767
-82% -$206K
AKTX
71
Akari Therapeutics
AKTX
$14.8M
$4.34M 0.24%
+84
New +$4.75M
BLRX
72
BioLineRX
BLRX
$12.2M
$4.24M 0.24%
+3,171
New +$5.21M
MGNX icon
73
MacroGenics
MGNX
$245M
$4.19M 0.23%
+150,553
New +$5.32M
ARWR icon
74
PUT
Arrowhead Research
ARWR
$12.1B
$4.07M 0.23%
2,478
+1,583
+177% +$27.8K
ALIM
75
DELISTED
Alimera Sciences
ALIM
$3.94M 0.22%
+33,333
New +$3.24M
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $396M in Q1 2014, closing 92 positions and reducing 54 holdings. Its most notable exit was MannKind Corp, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, up from 9.1% a quarter earlier, followed by Energy and Communication Services.

Against the trend, Sabby Management opened a new position in Tenax Therapeutics worth $11.8M.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.